Does Alpha Lipoic Acid Lower Blood Pressure?

Alpha lipoic acid (ALA) does appear to lower blood pressure, though the effect is modest and depends heavily on who is taking it. A 2023 meta-analysis of randomized controlled trials found that ALA supplementation reduced systolic blood pressure by about 5 mmHg and diastolic by about 3 mmHg on average. Those numbers matter more for people who already have elevated blood pressure than for people whose readings are normal, and the story beneath the averages reveals a supplement that works through several indirect routes rather than acting like a conventional blood pressure drug.

What the Pooled Trial Data Actually Show

The most comprehensive look at ALA and blood pressure comes from a dose-response meta-analysis of randomized controlled trials published in Frontiers in Cardiovascular Medicine. Pooling the available evidence, ALA supplementation reduced systolic blood pressure by roughly 5.5 mmHg and diastolic blood pressure by about 3.4 mmHg compared to placebo.¹ Those reductions were statistically significant, meaning they were unlikely to be due to chance alone. To put them in context, a 5 mmHg drop in systolic pressure is in the same neighborhood as what you might get from cutting salt intake or starting a walking routine. It is not dramatic, but it is clinically meaningful over time when sustained.

The meta-analysis also found that the effect was strongest at doses below 800 mg per day and when supplementation lasted 12 weeks or less. That might sound counterintuitive, but it likely reflects the makeup of the trials included: the shorter, lower-dose studies may have enrolled participants who were more responsive, or ALA’s antioxidant effects may plateau after a certain period. A separate meta-analysis published in Arterial Hypertension confirmed the general direction of these findings and added an important wrinkle: the blood pressure reduction was statistically significant in people who already had elevated or high blood pressure, but not in people with normal readings.²

Who Benefits and Who Does Not

This is where the evidence gets genuinely useful for individual decision-making. If your blood pressure is already in a healthy range, ALA is unlikely to push it noticeably lower. A study in healthy young men found that neither oral nor intra-arterial ALA had any effect on blood pressure, arterial stiffness, or markers of oxidative stress.³ In a system that is already functioning well, ALA does not seem to have much to fix.

The people who stand to gain the most are those dealing with metabolic problems. ALA has documented effects across several features of metabolic syndrome, including high blood pressure, insulin resistance, and abnormal blood lipids.⁴ This makes sense mechanistically: metabolic syndrome involves a web of oxidative stress, inflammation, and insulin dysfunction, and ALA targets multiple nodes in that web simultaneously. If your blood pressure is elevated alongside other metabolic issues like prediabetes or obesity, ALA may offer more benefit than if hypertension is your only concern.

People with diabetes also appear to respond, though the picture is more complex. In diabetic patients, ALA improved nitric oxide-mediated blood vessel relaxation, an effect that was not seen in healthy controls.⁵ The improvement was comparable to what high-dose vitamin C achieved in the same study, suggesting ALA’s antioxidant properties are doing the heavy lifting in people whose blood vessels are under oxidative assault.

How ALA Influences Blood Vessels

ALA does not lower blood pressure by blocking the same receptors that conventional antihypertensive drugs target. Instead, it works upstream, primarily by protecting the cells that line your blood vessels and helping them produce nitric oxide, the molecule that signals blood vessels to relax and widen. A systematic review of human studies concluded that ALA improves endothelial function by increasing nitric oxide availability while simultaneously reducing oxidative stress and inflammation.⁶

The specifics of how it boosts nitric oxide have been mapped out in laboratory studies. ALA activates a signaling pathway that leads to phosphorylation (essentially, turning on) of the enzyme responsible for producing nitric oxide in blood vessel walls. When that enzyme is activated, vessels release more nitric oxide, and the vessel wall relaxes.⁷ This process becomes particularly relevant with aging. In older animals, the activity of that enzyme declines, contributing to stiffer arteries and higher blood pressure. Treating aged rats with the R-form of ALA partially restored the enzyme’s activity, suggesting ALA may counteract one of the vascular consequences of aging.⁸

ALA also targets oxidative stress more directly. In a rat model of high-salt hypertension, ALA supplementation reduced levels of damaging reactive oxygen species in the brain region that controls sympathetic nervous activity, effectively calming the “fight or flight” signals that raise blood pressure. Treated rats showed lower mean arterial pressure and reduced sympathetic nerve activity compared to untreated hypertensive rats.⁹ In another animal model, ALA prevented the rise in blood pressure, the buildup of tissue damage products in arteries, and the spike in heart mitochondrial free radical production that occurred with chronic high-glucose feeding.¹⁰

The Inflammation Connection

Chronic low-grade inflammation stiffens arteries and raises blood pressure over time. ALA has a solid track record of lowering inflammatory markers in clinical trials, which likely contributes to its blood pressure effects even though it is not the same thing as directly lowering blood pressure. A meta-analysis of randomized trials found that ALA supplementation significantly reduced C-reactive protein (CRP), a widely used marker of systemic inflammation, particularly when baseline CRP was already elevated and when supplementation lasted more than eight weeks.¹¹

The anti-inflammatory effects go beyond CRP. In patients with metabolic conditions, ALA supplementation significantly lowered levels of interleukin-6 and tumor necrosis factor alpha, two inflammatory molecules that promote blood vessel damage and stiffness.¹² A study in type 2 diabetes patients who had previously suffered a heart attack showed that four months of ALA treatment reduced CRP by about 31%, interleukin-6 by about 30%, and tumor necrosis factor alpha by about 23%.¹³ These are not trivial reductions, and in patients whose cardiovascular systems are being battered by chronic inflammation, dampening that inflammatory load would be expected to benefit blood pressure over time even if the effect on a pressure reading at any single doctor’s visit is subtle.

What Happens When ALA Meets Other Treatments

If you are already on blood pressure medication, the question becomes whether adding ALA provides any additional benefit. The answer is mixed. In a study of diabetic patients with stage 1 hypertension who were taking quinapril (an ACE inhibitor), the drug itself reduced blood pressure by about 10%. Adding ALA on top of that did not push blood pressure any lower.¹⁴ This suggests that when a powerful pharmaceutical is already addressing the same pathways, ALA may not have room to add much on the blood pressure front specifically.

A different combination tells a different story. When ALA was paired with acetyl-L-carnitine (another mitochondrial supplement) in people with coronary artery disease, the combination increased brachial artery diameter, indicating reduced arterial tone. The blood pressure effect for the group as a whole only trended toward significance, but in the subgroup whose blood pressure started above the median, systolic pressure dropped from about 151 to 142 mmHg. The subgroup with metabolic syndrome saw a similar drop, from about 139 to 130 mmHg.¹⁵ This reinforces the pattern: ALA-based interventions work best in people whose blood pressure is already elevated, and the benefit may require more than ALA alone to become substantial.

Vascular Effects Beyond the Blood Pressure Cuff

Some of ALA’s cardiovascular benefits show up in measurements that a standard blood pressure check would miss. In a placebo-controlled trial of overweight and obese adolescents, three months of ALA supplementation did not change flow-mediated dilation (a standard test of how well arteries respond to increased blood flow). However, ALA did produce a significant widening of the brachial artery both at rest and at peak dilation compared to placebo.¹⁶ That is a meaningful structural change. Wider arteries at rest mean less resistance for the heart to pump against, which over time can translate to lower blood pressure even if the standard flow-mediated dilation test does not capture it in the short term.

ALA has also shown effects on cardiac nerve signaling. In patients who had experienced takotsubo cardiomyopathy (a stress-induced heart condition), ALA improved sympathetic nerve function to the heart over 12 months compared to placebo.¹⁷ This is a niche application, but it suggests ALA’s cardiovascular reach extends beyond simple antioxidant scavenging into the nervous system connections that regulate heart function.

R-Form, Racemic, and Getting Enough Into Your Blood

Most ALA supplements sold commercially contain a 50/50 mix of two mirror-image forms: R-lipoic acid (the form your body produces naturally) and S-lipoic acid (a synthetic byproduct of manufacturing). This matters because the two forms are not absorbed equally. In a pharmacokinetic study of healthy volunteers, the R-form had an absolute oral bioavailability of about 38%, while the S-form came in at about 28%. From tablet formulations, those numbers dropped to roughly 25% and 20% respectively.¹⁸ Either way, most of what you swallow does not make it into your bloodstream. ALA is rapidly absorbed but also rapidly cleared, with a half-life measured in minutes rather than hours.

Age complicates the picture further. A pilot study comparing younger and older adults found that bioavailability was much more variable in older subjects. Some older men actually absorbed the R-form better from a pure R-lipoic acid supplement than from the standard racemic mix, while younger men tended to absorb more from the racemic version.¹⁹ This variability means that two people taking the same dose may end up with very different blood levels, which could partly explain why some individuals notice effects and others do not.

Across different tablet formulations, absorption was generally rapid, with peak blood levels reached within about 20 to 30 minutes. Total absorption (measured by area under the curve) was reasonably comparable between formulations, though peak concentration varied more.²⁰ Taking ALA on an empty stomach generally improves absorption, because food competes for the same intestinal transporters. If you are trying to get a blood pressure benefit, consistency and timing may matter as much as the dose on the label.

Safety and a Rare but Serious Side Effect

At typical supplement doses (300 to 600 mg per day), ALA is generally well tolerated. The most common complaints are mild gastrointestinal issues like nausea, and these tend to improve with food or lower doses. However, there is one rare side effect worth knowing about: insulin autoimmune syndrome, a condition in which the body develops antibodies against its own insulin, leading to episodes of severe low blood sugar.

Case reports have documented this happening after ALA supplementation. In two Indian patients, ALA triggered the condition with very different severity: one required oral steroids tapered over several months, while the other recovered with dietary changes alone after stopping ALA.²¹ The condition has also been reported in a Caucasian patient whose elevated insulin antibody levels were traced to ALA supplement use, and whose diagnosis spared her from unnecessary surgery that had been considered before the connection was identified.²²

This side effect is rare, but it is worth being aware of, especially if you experience unexplained episodes of dizziness, shakiness, or confusion after starting ALA. The condition resolves after stopping the supplement in most reported cases. People who are already on blood-sugar-lowering medications should be particularly cautious, since ALA can amplify the hypoglycemic effect.

How Much ALA You Get From Food

ALA is found naturally in organ meats like liver, kidney, and heart, and in smaller amounts in fruits and vegetables. But the amounts from food are tiny compared to supplement doses. A comprehensive review noted that it is unlikely anyone gets appreciable amounts of ALA from a typical Western diet, and that supplements ranging from 50 to 600 mg represent the primary source in virtually all clinical research.²³ If you are interested in ALA specifically for cardiovascular effects, food sources alone are not going to get you there. The doses used in blood pressure trials are orders of magnitude higher than what you would get from even an organ-meat-heavy diet.

Animal Research and What It Cannot Tell You

Much of the mechanistic understanding of ALA and blood pressure comes from animal models, and it is worth being candid about their limits. A study using a well-established rat model of hypertension (two-kidney-one-clip, which mimics certain types of human hypertension) found that two weeks of ALA treatment improved vascular reactivity but did not reverse the structural heart enlargement or kidney damage caused by the hypertension.²⁴ That result neatly captures the state of the evidence overall: ALA can tweak the vascular system in favorable directions, but it is not powerful enough to undo established structural damage. The animal studies showing prevention of hypertension (like the glucose-fed rat model mentioned earlier) are more encouraging than the studies trying to reverse existing disease, which aligns with the clinical picture of ALA working better as a supportive measure than as a standalone treatment for established hypertension.

This gap between prevention and reversal shows up repeatedly across the research. ALA looks most promising when given before or during the development of metabolic and vascular dysfunction, rather than after the damage is entrenched. For a person with early-stage blood pressure elevation and metabolic risk factors, the evidence is more encouraging than for someone with longstanding, poorly controlled hypertension who has already developed structural changes in the heart or arteries.